Acipimox inhibits human carbonic anhydrases

References

• a) Lovisolo PP, Briatico-Vangosa G, Orsini G, et al. Pharmacological profile of a new antilipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) II - Antilipolytic and blood lipid lowering activity. Pharmacol Res Commun 1981;13:163–74.
   PubMedGoogle Scholar
  b) Fuccella LM, Goldaniga G, Lovisolo P, et al. Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther 1980;28:790–5.
   PubMed Web of Science ®Google Scholar
• a) Stirling C, McAleer M, Reckless JP, et al. Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa. Clin Sci 1985;68:83–8. b) Singh A, Faccenda D, Campanella M. Pharmacological advances in mitochondrial therapy. EBioMedicine 2021;65:103244.
   Web of Science ®Google Scholar
  c) Lintott CJ, Scott RS, Bremer JM. Treatment of hyperlipidaemia with acipimox. Curr Med Res Opin 1989;11:374–9.
   PubMed Web of Science ®Google Scholar
• a) Locci Cubeddu T, Masiello P, Pollera M, Bergamini E. Effects of antilipolytic agents on rat liver peroxisomes and peroxisomal oxidative activities. Biochim Biophys Acta 1985;839:96–104.
   PubMedGoogle Scholar
  b) Bergamini E. Searching for the fountain of autophagy-dependent youth: Ettore Bergamini. Interview by Daniel J. Klionsky. Autophagy 2012;8:1169–74.
   PubMed Web of Science ®Google Scholar
• a) Cavallini G, Donati A, Bergamini E. Antiaging therapy: a novel target for antilipolytic drugs. Mini Rev Med Chem 2014;14:551–6.
   PubMed Web of Science ®Google Scholar
  b) Cavallini G, Donati A, Taddei M, Bergamini E. Peroxisomes proliferation and pharmacological stimulation of autophagy in rat liver: evidence to support that autophagy may remove the "older" peroxisomes. Mol Cell Biochem 2017;431:97–102.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors? J Enzyme Inhib Med Chem 2018;33:485–95.
   PubMed Web of Science ®Google Scholar
  b) Cadoni R, Pala N, Lomelino C, et al. Exploring heteroaryl-pyrazole carboxylic acids as human carbonic anhydrase XII inhibitors. ACS Med Chem Lett 2017;8:941–6.
   PubMed Web of Science ®Google Scholar
  c) Langella E, D'Ambrosio K, D'Ascenzio M, et al. A combined crystallographic and theoretical study explains the capability of carboxylic acids to adopt multiple binding modes in the active site of carbonic anhydrases. Chemistry 2016;22:97–100.
   PubMed Web of Science ®Google Scholar
  d) Cvijetić IN, Tanç M, Juranić IO, et al. 5-Aryl-1H-pyrazole-3-carboxylic acids as selective inhibitors of human carbonic anhydrases IX and XII. Bioorg Med Chem 2015;23:4649–59.
   PubMed Web of Science ®Google Scholar
• Annunziato G, Angeli A, D'Alba F, et al. Discovery of new potential anti-infective compounds based on carbonic anhydrase inhibitors by rational target-focused repurposing approaches. ChemMedChem 2016;11:1904–14.
   PubMed Web of Science ®Google Scholar
• a) Cau Y, Vullo D, Mori M, et al. Potent and selective carboxylic acid inhibitors of tumor-associated carbonic anhydrases IX and XII. Molecules 2017;23:17.
   PubMed Web of Science ®Google Scholar
  b) Cau Y, Mori M, Supuran CT, Botta M. Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations. Org Biomol Chem 2016;14:8322–30.
   PubMed Web of Science ®Google Scholar
  c) Mori M, Cau Y, Vignaroli G, et al. Hit recycling: discovery of a potent carbonic anhydrase inhibitor by in silico target fishing. ACS Chem Biol 2015;10:1964–9.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT, Carbonic anhydrase inhibitors: designing isozyme-specific inhibitors as therapeutic agents. In: Chegwidden WR, Carter ND, eds. The carbonic anhydrases: current and emerging therapeutic targets. Cham: Springer International Publishing; 2021; p. 221–235;
   Google Scholar
  b) Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2021;36:561–80.
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.
   PubMed Web of Science ®Google Scholar
  d) Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–62.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT. Novel carbonic anhydrase inhibitors. Future Med Chem 2021;13:1935–7.
   PubMed Web of Science ®Google Scholar
  b) Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur J Med Chem 1996;31:1001–10.
   Web of Science ®Google Scholar
  c) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.
   PubMed Web of Science ®Google Scholar
  d) Rotondi G, Guglielmi P, Carradori S, et al. Design, synthesis and biological activity of selective hCAs inhibitors based on 2-(benzylsulfinyl)benzoic acid scaffold. J Enzyme Inhib Med Chem 2019;34:1400–13.
   PubMed Web of Science ®Google Scholar
• a) D'Ambrosio K, Carradori S, Monti SM, et al. Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem Commun 2015;51:302–5.
   PubMed Web of Science ®Google Scholar
  b) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today? Med Res Rev 2020;40:2485–565.
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
  d) Alhameed RA, Berrino E, Almarhoon Z, et al. A class of carbonic anhydrase IX/XII - selective carboxylate inhibitors. J Enzyme Inhib Med Chem 2020;35:549–54.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol 2020;12:603–17.
   PubMedGoogle Scholar
  b) Winum JY, Rami M, Scozzafava A, et al. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev 2008;28:445–63.
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci (Lond) 2021;135:1233–49.
   PubMed Web of Science ®Google Scholar
  d) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.
   PubMed Web of Science ®Google Scholar
  e)) Supuran CT. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2021;30:1197–208.
   PubMed Web of Science ®Google Scholar
• a) Angeli A, Carta F, Nocentini A, et al. Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment. Metabolites 2020;10:412.
   PubMed Web of Science ®Google Scholar
  b) Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 - 2013). Expert Opin Ther Pat 2013;23:681–91.
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709–12.
   PubMed Web of Science ®Google Scholar
  d) Mincione F, Nocentini A, Supuran CT. Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opin Drug Discov 2021;16:1209–25.
   PubMed Web of Science ®Google Scholar
  e) Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;23:725–35.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 2016;16:961–8.
   PubMed Web of Science ®Google Scholar
  b) Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem 2016;31:894–9.
   PubMed Web of Science ®Google Scholar
  c) Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31:60–3.
   PubMed Web of Science ®Google Scholar
  d) Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;60:1159–70.
   PubMed Web of Science ®Google Scholar
  e) Dettori I, Fusco I, Bulli I, et al. Protective effects of carbonic anhydrase inhibition in brain ischaemia in vitro and in vivo models. J Enzyme Inhib Med Chem 2021;36:964–76.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Ferraroni M, Ward C, et al. Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells. Eur J Med Chem 2019;182:111600.
   PubMed Web of Science ®Google Scholar
• Behnke CA, Le Trong I, Godden JW, et al. Atomic resolution studies of carbonic anhydrase II. Acta Crystallogr D Biol Crystallogr 2010;66:616–27.
   PubMedGoogle Scholar
• Elder I, Fisher Z, Laipis PJ, et al. Structural and kinetic analysis of proton shuttle residues in the active site of human carbonic anhydrase III. Proteins 2007;68:337–43.
   PubMed Web of Science ®Google Scholar
• Vernier W, Chong W, Rewolinski D, et al. Thioether benzenesulfonamide inhibitors of carbonic anhydrases II and IV: Structure-based drug design, synthesis, and biological evaluation. Bioorg Med Chem 2010;18:3307–19.
   PubMed Web of Science ®Google Scholar
• Pilka ES, Kochan G, Oppermann U, Yue WW. Crystal structure of the secretory isozyme of mammalian carbonic anhydrases CA VI: implications for biological assembly and inhibitor development. Biochem Biophys Res Commun 2012;419:485–9.
   PubMed Web of Science ®Google Scholar
• Buemi MR, Di Fiore A, De Luca L, et al. Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety . Eur J Med Chem 2019;163:443–52.
   PubMed Web of Science ®Google Scholar
• Leitans J, Kazaks A, Balode A, et al. Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX. J Med Chem 2015;58:9004–9.
   PubMed Web of Science ®Google Scholar
• Whittington DA, Waheed A, Ulmasov B, et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA 2001;98:9545–50.
   PubMed Web of Science ®Google Scholar
• Di Fiore A, Monti SM, Hilvo M, et al. Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins 2009;74:164–75.
   PubMed Web of Science ®Google Scholar
• La Regina G, Coluccia A, Famiglini V, et al. Discovery of 1,1'-biphenyl-4-sulfonamides as a new class of potent and selective carbonic anhydrase XIV inhibitors. J Med Chem 2015;58:8564–72.
   PubMed Web of Science ®Google Scholar
• Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 16 Rev. C.01. Wallingford, CT, 2016.
   Google Scholar
• Verdonk ML, Cole JC, Hartshorn MJ, et al. Improved protein-ligand docking using GOLD. Proteins 2003;52:609–23.
   PubMed Web of Science ®Google Scholar
• Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727–48.
   PubMed Web of Science ®Google Scholar
• Case DA, Cheatham TE, 3rd, Darden T, et al. The Amber biomolecular simulation programs. J Comput Chem 2005;26:1668–88.
   PubMed Web of Science ®Google Scholar
• Maier JA, Martinez C, Kasavajhala K, et al. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 2015;11:3696–713.
   PubMed Web of Science ®Google Scholar
• Wang J, Wolf RM, Caldwell JW, et al. Development and testing of a general amber force field. J Comput Chem 2004;25:1157–74.
   PubMed Web of Science ®Google Scholar
• Kuchlyan J, Martinez-Fernandez L, Mori M, et al. What makes thienoguanosine an outstanding fluorescent DNA probe? J Am Chem Soc 2020;142:16999–7014.
   PubMed Web of Science ®Google Scholar
• Ciaco S, Humbert N, Real E, et al. A class of potent inhibitors of the HIV-1 nucleocapsid protein based on aminopyrrolic scaffolds. Acs Med Chem Lett 2020;11:698–705.
   PubMed Web of Science ®Google Scholar
• Ballone A, Picarazzi F, Prosser C, et al. Experimental and computational druggability exploration of the 14-3-3ζ/SOS1pS1161 PPI interface. J Chem Inf Model 2020;60:6555–65.
   PubMed Web of Science ®Google Scholar
• Dragoni F, Boccuto A, Picarazzi F, et al. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral Res 2020;175:104708.
   PubMed Web of Science ®Google Scholar
• Roe DR, Cheatham TE. 3rd. PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. J Chem Theory Comput 2013;9:3084–95.
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
   PubMed Web of Science ®Google Scholar
• a) Pastorekova S, Casini A, Scozzafava A, et al. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:869–73.
   PubMed Web of Science ®Google Scholar
  b) Vullo D, Voipio J, Innocenti A, et al. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2005;15:971–6.
   PubMed Web of Science ®Google Scholar
  c) Gieling RG, Babur M, Mamnani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem 2012;55:5591–600.
   PubMed Web of Science ®Google Scholar
  d) Carta F, Supuran CT, Scozzafava A. Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Med Chem 2014;6:1149–65.
   PubMed Web of Science ®Google Scholar
• a) Sarikaya SB, Gülçin I, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of human erythrocyte isozymes I and II with a series of phenolic acids. Chem Biol Drug Des 2010;75:515–20.
   PubMed Web of Science ®Google Scholar
  b) Yıldırım A, Atmaca U, Keskin A, et al. N-Acylsulfonamides strongly inhibit human carbonic anhydrase isoenzymes I and II. Bioorg Med Chem 2015;23:2598–605.
   PubMed Web of Science ®Google Scholar
  c) Innocenti A, Gülçin I, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett 2010;20:5050–3.
   PubMed Web of Science ®Google Scholar
• a) Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024–31.
   PubMed Web of Science ®Google Scholar
  b) Oztürk Sarikaya SB, Topal F, Sentürk M, et al. In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds. Bioorg Med Chem Lett 2011;21:4259–62.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020;15:671–86.
   PubMed Web of Science ®Google Scholar
  b) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
  c) De Simone G, Alterio V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. Expert Opin Drug Discov 2013;8:793–810.
   PubMed Web of Science ®Google Scholar
• Alonso H, Bliznyuk AA, Gready JE. Combining docking and molecular dynamic simulations in drug design. Med Res Rev 2006;26:531–68.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42.
   PubMed Web of Science ®Google Scholar